Exagen (XGN) Competitors

Exagen (NASDAQ:XGN) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Do insiders and institutionals have more ownership in XGN or FTRE?

75.3% of Exagen shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 0.4% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend XGN or FTRE?

Exagen currently has a consensus target price of $11.25, suggesting a potential upside of 11.39%. Fortrea has a consensus target price of $12.22, suggesting a potential upside of 46.55%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortrea	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

Which has stronger valuation & earnings, XGN or FTRE?

Exagen has higher earnings, but lower revenue than Fortrea. Exagen is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$58.86M	3.78	-$15.11M	-$0.89	-11.35
Fortrea	$2.70B	0.28	-$328.50M	-$11.38	-0.73

Is XGN or FTRE more profitable?

Exagen has a net margin of -28.85% compared to Fortrea's net margin of -37.57%. Fortrea's return on equity of 5.25% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-28.85%	-130.38%	-34.69%
Fortrea	-37.57%	5.25%	1.72%

Which has more volatility & risk, XGN or FTRE?

Exagen has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Does the media refer more to XGN or FTRE?

In the previous week, Fortrea had 6 more articles in the media than Exagen. MarketBeat recorded 9 mentions for Fortrea and 3 mentions for Exagen. Exagen's average media sentiment score of 0.99 beat Fortrea's score of 0.80 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exagen beats Fortrea on 9 of the 17 factors compared between the two stocks.